secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001829126-25-002334
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel reports Q4 net loss $3.0M; pro forma cash $7.2M; deconsolidates unit; board appointments
--------------------------------------------------------------------------------

- Net loss of $3.0M for Q4 2024 and $11.2M for full year; cash of $3.1M at Dec 31, 2024.
- Pro forma cash $7.2M including $4.1M equity financing post-quarter; cash runway into Q2 2025.
- Focusing on plogosertib (PLK1 inhibitor) acquired from Cyclacel Ltd; new oral formulation in development.
- Deconsolidation of Cyclacel Ltd expected to increase equity by ~$5.0M and significantly reduce R&D spend.
- Two new independent directors appointed: Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan; committee chairs set.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000182912625002334/0001829126-25-002334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000182912625002334/cyclacel_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-002334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer